At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 20 Jul 2001 No-Development-Reported for Cancer in USA (Unknown route)
- 05 Feb 1998 Preclinical development for Cancer in USA (Unknown route)